Open AccessPosaconazole‐induced hypertension in children with cystic fibrosis
Author(s) -
Marpole Rachael,
Yeoh Daniel K.,
Withers Adelaide L.
Publication year - 2021
Publication title -
respirology case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.304
H-Index - 9
ISSN - 2051-3380
DOI - 10.1002/rcr2.822
Subject(s) - posaconazole , medicine , cystic fibrosis , allergic bronchopulmonary aspergillosis , antifungal , aspergillosis , dermatology , itraconazole , immunology , immunoglobulin e , antibody
Posaconazole is a triazole antifungal with a broad spectrum of activity against moulds including Aspergillus spp. Emerging data suggest posaconazole may be effective in the treatment of allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis (CF). Rarely, posaconazole can cause pseudohyperaldosteronism, manifesting as hypertension and electrolyte abnormalities, with a number of cases recently reported in individuals without CF. We describe two cases of children with CF who developed hypertension, likely due to pseudohyperaldosteronism, following the initiation of posaconazole for the treatment of ABPA.